Innovation

GBS Toxin Receptor

Vanderbilt University
posted on 01/25/2010

-


Innovation Details
 

Detailed Description

Vanderbilt researchers have uncovered a novel finding for the toxin from Group beta-hemolytic Streptococcus bacteria (GBS toxin). This group has shown that the GBS toxin may be used as vascular targeting agent to destroy pathological vasculature present in malignant tumors, atherosclerosis, rheumatoid arthritis and chronic wounds.

Supplemental Documents
VU9861—GBS Toxin Receptor

Inventors
Changlin Fu
Carl Hellerqvist


CONTACT
Janis Elsner
(615) 343-2430
janis.elsner@vanderbilt.edu

File Number: MKT9861  


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at Vanderbilt University for more information.

request more info
People

No people are currently associated with this innovation.

[?]
Followed By

Follow this innovation



No one is following this innovation.

Organization
1849

Vanderbilt University


Profile
Related Tags

Find more innovations

February 11, 2009

4,065 members 12,304 innovations 109 organizations

Browse

Alan Thomas - Director - UChicagoTech

"The iBridge Network has opened up new avenues for innovations at UChicagoTech. Relationships between researchers from other universities or industry can be built and strengthened, while investors can find new technologies to advance. "  read more...